Copyright © 2019. Inderes Oy. All rights reserved.
Search
User account

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Log in
BBS-Bioactive Bone Substitutes
1053 investors follow this company
The company is not covered. See all listed companies from here.
BUY 2.02 LOWEST 2.00 VOLUME 1 133
SELL 2.12 HIGHEST 2.10 VALUE 0,002 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Latest insider trading

Type: stock_exchange_release
22.10.
2019

22.10.2019

BBS-Bioactive Bone Substitutes Plc: The patent application regarding a bone protein preparation has been accepted in Canada

Our company BBS-Bioactive Bone Substitutes Plc’s patent application ”A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION CONTAINING POLYETHYLENE GLYCOL/GLYCEROL MATRIX AND CALCIUM SALT GRANULES” has been accepted in Canada. The same European and Eurasian patent has been valid about three years.

Type: stock_exchange_release
14.10.
2019

The Board of BBS OYj has today nominated PhD Ilkka Kangasniemi as the CEO of the company, starting 15th of October 2019. Dr. Kangasniemi, who joined the board in the spring 2019, is experienced in commercialization and development of biomaterials and has been in the board and management of several biotech companies.
Short term goals of BBS include transition of the company into a marketing and sales organization.

Type: stock_exchange_release
30.8.
2019

BBS-Bioactive Bone Substitutes Plc (BBS) Interim Report January 1th  – June 30th 2019 (unaudited)

January-June shortly (comparison season 1-6/2018)

Type: stock_exchange_release
30.8.
2019

BBS-Bioactive Bone Substitutes Plc (BBS) Interim Report January 1th  – June 30th 2019 (unaudited)

January-June shortly (comparison season 1-6/2018)

Type: stock_exchange_release
9.7.
2019

Correction to BBS share issue completed 215 new shareholders in Sweden Equity Market Information release, published the 2nd of July 2019 at 9:00 CEST.
The release was published as an Equity Market Information release but should have been released as a Company Announcement. The content of the release is the same as before.

Type: stock_exchange_release
2.7.
2019

BBS – Bioactive Bone Substitutes Oyj (“BBS or “Company”), an innovator in orthobiologics, today announced the final outcome of the share issue to increase the number of shareholders in Sweden (“Offering”), for which the subscription period ended on June 30, 2019. The subscription price of the Offering has been set to SEK 28,10 per share. A total of 114 300 new shares were subscribed in the Offering and the Board of Directors has today decided to approve the subscriptions.

Type: stock_exchange_release
28.6.
2019

BBS – Bioactive Bone Substitutes Oyj (“BBS or “Company”), an innovator in orthobiologics, announces that the subscription price per share in its ongoing share issue (the “Offering”) is 28,10 SEK. The subscription price corresponds to a discount of 12% compared with the closing price of the Company’s share on Nasdaq First North Sweden on Friday June 28, 2019. The Offering comprises up to a maximum of 509,000 new shares (the “Offer Shares”), circa 10% of present number of shares in the Company, for subscription to investors in Sweden.

Type: stock_exchange_release
24.6.
2019

BBS – Bioactive Bone Substitutes, an innovator in orthobiologics, today announced that the company’s ARTEBONE® production line is ready for the audit required for CE marking. Following a successful audit, the certified production line will meet the regulatory requirements to manufacture a medical device in the European Union (EU). This is an important step towards obtaining the CE marking for the company’s first product, ARTEBONE® ready-to-use paste, during the first half of 2020.

Type: stock_exchange_release
17.6.
2019

                                                       
The Board of Directors of BBS – Bioactive Bone Substitutes Oyj (“BBS” or “Company”), an innovator in orthobiologics, has today decided to conduct a share issue based on the authorization granted at the Annual General Meeting on 05 April 2019 (the “Offering”). The Offering comprises up to 509,000 new shares (the “Offer Shares”), circa 10% of present number of shares in the company, for subscription to investors in Sweden.

The Offering in short

Type: stock_exchange_release
29.5.
2019

BBS – Bioactive Bone Substitutes, an innovator in orthobiologics, today announced that the company’s Chief Commercial Officer (CCO) Paul Watkins will present the company at Småbolagsdagen in Stockholm on June 3, 2019.

BBS-Bioactive Bone Substitutes

English translation unavailable for BBS-Bioactive Bone Substitutes.
BBS-Bioactive Bone Substitutes